Page 2 - Morphosys Company Profile Get Rating News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morphosys company profile get rating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morphosys Company Profile Get Rating Today - Breaking & Trending Today

MorphoSys (NASDAQ:MOR) Receives Buy Rating from JMP Securities

JMP Securities reiterated their buy rating on shares of MorphoSys (NASDAQ:MOR – Get Rating) in a report issued on Friday morning, MarketBeat Ratings reports. The brokerage currently has a $41.00 price target on the stock. MOR has been the subject of several other research reports. Zacks Investment Research raised MorphoSys from a sell rating to […] ....

Morgan Stanley , Goldman Sachs Group Inc , Morphosys Company Profile Get Rating , Zacks Investment Research , Quadrant Capital Group , Us Bancorp , Get Rating , Marketbeat Ratings , Investment Research , Capital Group , Goldman Sachs Group , Sachs Group , Sys Company Profile , Proprietary Development , Partnered Discovery , Nasdaq Mor , Reiterated Rating , Jmp Securities ,

MorphoSys (NASDAQ:MOR) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of MorphoSys (NASDAQ:MOR – Get Rating) from a sell rating to a hold rating in a research report report published on Wednesday, Zacks.com reports. According to Zacks, “MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company’s proprietary portfolio consists of MOR208, MOR202, […] ....

Morgan Stanley , Alphacentric Advisors , Morphosys Company Profile Get Rating , Zacks Investment Research , Blackrock Inc , Millennium Management , Quadrant Capital Group , Get Rating , Centric Advisors , Capital Group , Sys Company Profile , Proprietary Development , Partnered Discovery , Nasdaq Mor ,